Sumitovant offered $22.75 per share in cash, valuing Myovant at $2.4bn total, to acquire what it does not hold as a result of its 2019 agreement to buy majority shares of five Roivant companies. 

First FDA-hosted workshop on rare family of mitochondrial diseases offers plenty of opportunities to talk challenges in R&D – and identify some solutions.

A series of basic research insights around the cell death process called ferroptosis could form the underpinnings of a new class of treatments aimed at drug resistant tumors.

Newron Pharmaceuticals will file its investigational drug sarizotan in 2018 for respiratory issues in patients with Rett syndrome, setting it up to be the first therapy specifically indicated for this rare genetic disease. CEO Stefan Weber spoke to Scrip about Newron's commercial strategy for sarizotan and broader prospects for the evolving drug developer.